不同剂量丝裂霉素C膀胱灌注治疗Ta期膀胱移行细胞癌术后的临床观察

目的比较不同剂量丝裂霉素C（Mitomycin C,MMC）膀胱灌注治疗Ta期膀胱移行细胞癌（Ta-bladder transitional cell carcinoma,Ta-BTCC）术后的疗效及副作用。方法将114例Ta-BTCC术后患者随机分成A、B、C组,每组38例,A组给予20mg、B组给予40mg和C组给予60mg MMC行膀胱灌注治疗,并作随访12～20个月,平均16个月,观察患者的疗效及不良反应情况。结果 B组（40mg）的副作用较C组（60mg）轻（P〈0.05）,膀胱癌复发率较A组（20mg）低（P〈0.05）。结论 MMC灌注剂量为40mg时不良反应更轻,肿瘤复发率较低,是目前Ta-BTCC术后较理想的灌注剂量。

Clinical observation about different doses of Mitomycin C intravesical treatment of Ta Bladder transitional cell carcinoma(Ta-BTCC)

OBJECTIVE To compare with the efficacy and side effects of intravesical treatment of Ta-BTCC by using different doses of Mitomycin C(MMC).METHODS 114 cases of Ta-BTCC patients were randomly divided into 3 groups,A,B and C.Each group has 38 cases.For the patients of Group A,we took intravesical treatment with 20mg MMC,while 40mg for Group B and 60mg for Group C.And made followup of 12～20 months(an average of 16 months)to observe the efficacy and adverse reactions in patients with the role of the situation.RESULTS The adverse reactions of Group B(40mg)was less than Group C(60mg),(P<0.05),and the recurrence rate of bladder cancer in Group B was lower than in Group A(P<0.05).CONCLUSION When MMC infusion dose is 40mg,the adverse reactions is lighter and lower rate of tumor recurrence and is the ideal dose for Ta-BTCC currently.